2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö : 2023-06-10
±³À°ÀÏÀÚ : 2023-06-10
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü(ÄÁº¥¼ÇȦ)
±³À°ÁÖÁ¦ : 2023 Àü¸³¼±¾Ï°¡À̵å¶óÀÎ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 02-2038-7988
À̸ÞÀÏ : gaonpco@gaonpco.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇ»çÇÐ, ÀÇÇб³À°
Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 55ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï -Àü¹®ÀÇ 20,000¿ø -Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø 10,000¿ø -ÇöÀåµî·Ï ºÒ°¡
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:10~09:25 Genetic test of prostate cancer based on clinical practice: When, How, Who? ±è¿øÅÂ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:25~09:40 Is PSA sufficient to screening for prostate biopsy? : PSA kinetics, New biomarker (PHI, 4K, etc.) or mpMRI ÀÌÁ¾¼ö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:40~09:55 What is the optimal technique in the era of MR-targeted biopsies and PSMA-PET/CT? ÀÌÇйÎ(¼¿ïÀÇ´ë)
Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 09:55~10:10 Discussion ¼ÛÇÊÇö(¿µ³²ÀÇ´ë)
ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:10~10:30 Coffee Break ()
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:30~10:45 Which option is considered the most effective for localized low-risk prostate cancer in 2023 : active surveillance, surgery, or radiation therapy? ½ÅÅÃÁØ(°è¸íÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 10:45~11:00 Changing evidence and guidelines for monitoring during active surveillance À¯¼ºÇö(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:00~11:15 Current guidelines of focal therapy in treating prostate cancer ±èº´ÈÆ(°è¸íÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:15~11:35 Discussion ÀüȲ±Õ(¼º±Õ°üÀÇ´ë)
½Ä»ç 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 11:35~12:35 Lunch ()
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:35~12:50 Real clinical advantage of neoadjuvant ADT before radical prostatectomy. ÃÖ¼¼¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 12:50~13:05 Treatment guidelines for cN0 and cN1 Źü½Ä(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:05~13:20 Treatment guidelines for pN0 and pN1 after radical prostatectomy ÃÖ¼¼¹Î(°æ»óÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:20~13:40 Discussion ()
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:40~13:55 What are the prophylactic or treatment options for voiding dysfunction following RP or RT? ¹ÚÇü±Ù(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 13:55~14:10 What are the prophylactic or treatment options for erectile dysfunction following RP or RT? ÇÏÀ±¼®(°æºÏÀÇ´ë)
Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:10~14:25 Discussion ¹ÚÀ翵(°í·ÁÀÇ´ë)
ÈÞ½Ä 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:25~14:45 Coffee Break ()
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 14:45~15:00 Guidelines of radiotherapy for distant metastases ¼¿øÀÍ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:00~15:15 What is oligometastatic prostate cancer and how should it be treated in the era of PSMA-PET/CT? ±èÁ¾¿í(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:15~15:30 What should be selected as the first treatment for mHSPC in actual clinical practice? Á¶Á¤±â(ÇѾçÀÇ´ë)
Åä·Ð 06¿ù 10ÀÏ ÄÁº¥¼ÇȦ 15:30~15:45 Discussion ()